In this video, psychiatric nurse practitioner Amy LaCouture, PMHNP-BC, shares her experiences with INGREZZA® (valbenazine) capsules. Amy works in a community-based care setting with patients diagnosed with schizophrenia, bipolar disorder, or major depressive disorder. Amy explains why she chooses INGREZZA for her adult patients with TD. She discusses the efficacy and safety results from the INGREZZA clinical trials, and explains the convenient dosing schedule.
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and commercializing life-changing treatments for people with serious, challenging and under-addressed disorders. The company's diverse portfolio includes four FDA-approved treatments as well as clinical programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms. For more information, visit neurocrine.com, and follow the company on LinkedIn.
AT NEUROCRINE BIOSCIENCES WE PRIDE OURSELVES ON HAVING A STRONG, INCLUSIVE AND POSITIVE CULTURE BASED ON OUR SHARED MISSION AND VALUES.
To relieve patient suffering and enhance lives.
PASSION: We are driven and love what we do. We are committed to our goals and to making a difference.
INTEGRITY: We do the right thing for patients and our community. We take accountability. We speak up.
COLLABORATION: We trust one another. We are inclusive. We are respectful. We are transparent. Together we succeed.
INNOVATION: We seek and create optimal solutions.
TENACITY: We do not quit. We adapt. We accomplish what others cannot.
INGREZZA® (valbenazine) capsules is a prescription medicine used to treat adults with movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).
It is not known if INGREZZA is safe and effective in children.
Dosing and Administration Information
The initial dosage for INGREZZA is 40 mg once daily. After one week, increase the dose to the recommended dosage of 80 mg once daily. Continuation of 40 mg once daily may be considered for some patients. Administer INGREZZA orally with or without food
The Montana Psychiatry Conference makes every attempt to provide accurate and timely content available for users. Neither MPC nor third-party content providers are responsible or liable for any such content, including advertising, products or other materials available through third party sites.